Business News • PR NewsWire • Portola Pharmaceuticals Announces Data Presentations Highlighting Syk/JAK Inhibitor Clinical Development Program at 52nd American Society of Hematology Annual Meeting

Portola Pharmaceuticals Announces Data Presentations Highlighting Syk/JAK Inhibitor Clinical Development Program at 52nd American Society of Hematology Annual Meeting

Portola Pharmaceuticals Announces Data Presentations Highlighting Syk/JAK Inhibitor Clinical Development Program at 52nd American Society of Hematology Annual Meeting

SOUTH SAN FRANCISCO, Calif., Dec. 4, 2010 /PRNewswire/ -- Portola Pharmaceuticals, Inc. today announced the presentation of preclinical study results for its novel Syk and JAK inhibitor program at the American Society of Hematology's 52nd Annual Meeting and Exposition. Portola's novel Syk and JAK in

View More : http://www.prnewswire.com/news-releases/portola-pharmaceuticals-announces-data-presentations-highlighting-sykjak-inhibit...

Releted News by prnewswire

VH1's Divas Have Deployed!

Alaska Airlines Launches San Jose-Los Cabos, Mexico, Service

Blazingly Fast: Verizon Wireless Launches the World's Largest 4G LTE Wireless Network on Sunday, Dec. 5

Portola Pharmaceuticals Announces Data Presentations Highlighting Syk/JAK Inhibitor Clinical Development Program at 52nd American Society of Hematology Annual Meeting

The LEGO® Store Grand Re-Opening at Mall of America®

Breakthrough Therapies and a New Gene Target Advance the Treatment and Understanding of Hard-to-Treat Leukemias